{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Loan A"],"funding":["NIDDK NIH HHS"],"pagination":["1045-1055"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10749596"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(5)"],"pubmed_abstract":["Neurological disorders are a diverse group of conditions that affect the nervous system and include neurodegenerative diseases (Alzheimer's disease, multiple sclerosis, Parkinson's disease, Huntington's disease), cerebrovascular conditions (stroke), and neurodevelopmental disorders (autism spectrum disorder). Although they affect millions of individuals around the world, only a limited number of effective treatment options are available today. Since most neurological disorders express mitochondria-related metabolic perturbations, metformin, a biguanide type II antidiabetic drug, has attracted a lot of attention to be repurposed to treat neurological disorders by correcting their perturbed energy metabolism. However, controversial research emerges regarding the beneficial/detrimental effect"],"journal":["Neural regeneration research"],"pubmed_title":["Promising use of metformin in treating neurological disorders: biomarker-guided therapies."],"pmcid":["PMC10749596"],"funding_grant_id":["R01 DK120309"],"pubmed_authors":["Lui M","Loan A","He L","Syal C","Wang J"],"additional_accession":[]},"is_claimable":false,"name":"Promising use of metformin in treating neurological disorders: biomarker-guided therapies.","description":"Neurological disorders are a diverse group of conditions that affect the nervous system and include neurodegenerative diseases (Alzheimer's disease, multiple sclerosis, Parkinson's disease, Huntington's disease), cerebrovascular conditions (stroke), and neurodevelopmental disorders (autism spectrum disorder). Although they affect millions of individuals around the world, only a limited number of effective treatment options are available today. Since most neurological disorders express mitochondria-related metabolic perturbations, metformin, a biguanide type II antidiabetic drug, has attracted a lot of attention to be repurposed to treat neurological disorders by correcting their perturbed energy metabolism. However, controversial research emerges regarding the beneficial/detrimental effect","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-07-15T00:32:52.862Z","creation":"2025-04-06T19:17:17.837Z"},"accession":"S-EPMC10749596","cross_references":{"pubmed":["37862207"],"doi":["10.4103/1673-5374.385286"]}}